Threshold Pharmaceuticals Announces New Phase 1/2 Data On TH-302 In Multiple Myeloma to Be Presented At The 2014 ASH Annual Meeting
November 06, 2014 at 09:06 AM EST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data from an ongoing Phase 1/2 trial evaluating TH-302 and ...
